Clinical Trial

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).
Protocol Amendment History 6 changes
critical Primary endpoint(s) modified 2026-06-18
notable Enrollment increased: 60 -> 80 participants 2026-06-18
notable Trial sites expanded: 10 -> 14 locations 2026-06-18
notable Primary completion pushed: 2027-07 -> 2027-09 2026-06-18
minor Completion pushed: 2027-07 -> 2027-09 2026-06-18
notable Trial sites expanded: 7 -> 10 locations 2026-04-24
Trial Details
NCT Number NCT07259317
Lead Sponsor Corcept Therapeutics
Conditions Adenocarcinoma, Carcinoma, Pancreatic Ductal
Enrollment 80 participants
Start Date 2026-01-27
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-15